Stathas Theodoros, Mallis Antonios, Mastronikolis Nicholas S, Naxakis Stefanos S, Dimaka Konstantina, Panogeorgou Theodora, Stavrou Stavros, Margaritis Vasilios, Kourousis Christos, Papadas Theodoros A
ENT Department, University Hospital of Patras, Patras, Greece.
ORL J Otorhinolaryngol Relat Spec. 2011;73(6):291-4. doi: 10.1159/000330275. Epub 2011 Sep 22.
To evaluate the use of metronidazole as a prophylactic agent against pharyngocutaneous fistula (PCF) formation.
Seventy patients who underwent total laryngectomy between 2000 and 2008 in our department were divided into two groups. The first group (M+ group) was placed on a 10-day metronidazole regimen (2 days prior to surgery and 7 days following). The second group (M- group) received only regular preoperative chemoprophylaxis.
In total, 17 (24.3%) incidents of PCF were reported, 3 of which were in the M+ group, with the remainder in the M- group. A statistically significant reduction in the PCF rate was noted in favor of metronidazole in the overall population (p = 0.005), as well as in the patient group that had received radiotherapy prior to surgery (p = 0.03).
Metronidazole administered for a total of 10 days pre- and postoperatively seems to lower the incidence rate of PCF formation.
评估甲硝唑作为预防咽皮肤瘘（PCF）形成的药物的应用效果。
2000年至2008年期间在我科接受全喉切除术的70例患者被分为两组。第一组（M+组）接受为期10天的甲硝唑治疗方案（术前2天和术后7天）。第二组（M-组）仅接受常规术前化学预防。
总共报告了17例（24.3%）PCF事件，其中3例在M+组，其余在M-组。总体人群中，PCF发生率在统计学上显著降低，表明甲硝唑有效（p = 0.005），在术前接受过放疗的患者组中也是如此（p = 0.03）。
术前和术后总共服用10天的甲硝唑似乎能降低PCF形成的发生率。
